“DT56a prevents postmenopausal osteoporosis.”

DT56a (Femarelle) stimulates bone formation in female rats.


OVX rats developed noticeable signs of osteoporosis, namely, significant decrease in
trabecular bone volume and in trabecular and cortical thickness. DT56a, like oestrogen,
restored the bone structure measurements of all tested parameters in the OVX rats to the
values obtained in the intact rats. In skeletal tissues, CK activity was elevated in both
treatment groups. However, in the uterus DT56a did not activate oestrogen receptors while
oestrogen did elevate CK activity.

Contact Us


TruLife Distribution
401 E. Las Olas Blvd Suite 1400
Fort Lauderdale, Florida

* The products and the claims made about specific products on or through the Website have not been evaluated by the United States Food and Drug Administration (not required) and are not intended to diagnose, treat, cure or prevent disease. The information provided on this Site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this Website for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional, and carefully read all information provided on or in any product label or packaging, before using any medication or nutritional, herbal or homeopathic product (including regarding any interactions between any medication you are currently taking and such products), before starting any treatment for a health problem, or if you have or suspect you might have a health problem. Unless advised by your healthcare professional, biological age should not be used to determine or alter any age-related health or medical treatments based on your chronological age.